Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Bosutinib Mixed with Applesauce or Yogurt
NCT04916769Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Infinity at 144 hours and Maximum Observed Plasma Concentration at 144 hours. Started Aug 2021; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04916769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916769.